Neuberger Berman Group
PACB icon

Neuberger Berman Group’s Pacific Biosciences PACB Stock Holding History

Neuberger Berman Group’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.8K Buy
30,941
+9,506
+44% +$17K ﹤0.01% 2124
2025
Q4 		$40.1K Buy
+21,435
New +$41.2K ﹤0.01% 2063
2025
Q1 		– Sell
-28,208
Closed -$51.6K – 2033
2024
Q4 		$51.6K Buy
28,208
+892
+3% +$1.74K ﹤0.01% 1881
2024
Q3 		$46.4K Buy
+27,316
New +$44.9K ﹤0.01% 1874
2024
Q1 		– Sell
-621,771
Closed -$6.1M – 1899
2023
Q4 		$6.1M Buy
621,771
+143,661
+30% +$1.17M 0.01% 868
2023
Q3 		$3.99M Buy
478,110
+65,361
+16% +$747K ﹤0.01% 929
2023
Q2 		$5.49M Buy
+412,749
New +$5.02M ﹤0.01% 864

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Neuberger Berman Group's PACB Position: Q1 2026 in Review

Neuberger Berman Group increased its Pacific Biosciences (PACB) stake by 44% in Q1 2026, buying an estimated $17K and bringing the position to 30,941 shares worth $40.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2124.

Neuberger Berman Group first reported a position in PACB in Q2 2023 and has held it in 7 quarters since. The position peaked at $6.1M in Q4 2023. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Neuberger Berman Group held 30,941 shares of Pacific Biosciences worth $40.8K as of Q1 2026.
  • Neuberger Berman Group bought 9,506 Pacific Biosciences shares in Q1 2026, an estimated $17K.
  • Pacific Biosciences made up ﹤0.01% of Neuberger Berman Group's portfolio in Q1 2026, its #2124 holding.
  • Neuberger Berman Group first reported a position in Pacific Biosciences in Q2 2023 and has held it in 7 quarters since.
  • Neuberger Berman Group's Pacific Biosciences position peaked at $6.1M in Q4 2023.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.